Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.
10.3803/EnM.2015.30.3.252
- Author:
Young Shin SONG
1
;
Jung Ah LIM
;
Young Joo PARK
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. yjparkmd@snu.ac.kr
- Publication Type:Review
- Keywords:
Mutation;
Thyroid neoplasms;
Asia;
Proto-oncogene proteins B-raf;
Ret-PTC fusion oncoproteins;
Oncogene proteins ras;
PPAR gamma;
Telomerase
- MeSH:
Asia;
Asian Continental Ancestry Group*;
Carcinogenesis;
Geography;
Humans;
Pathology, Molecular;
PPAR gamma;
Prevalence;
Prognosis;
Protein Kinases;
Proto-Oncogene Proteins B-raf;
Proto-Oncogenes;
Telomerase;
Thyroid Gland*;
Thyroid Neoplasms*
- From:Endocrinology and Metabolism
2015;30(3):252-262
- CountryRepublic of Korea
- Language:English
-
Abstract:
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase pathway. B-Raf proto-oncogene (BRAF) mutations are the most common mutations observed in papillary thyroid cancers (PTCs), followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor gamma (PPARgamma) rearrangements. Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter have recently been associated with clinicopathologic features, disease prognosis, and tumorigenesis in thyroid cancer. While the mutations underlying thyroid tumorigenesis are well known, the frequency of these mutations is strongly associated with geography, with clear differences reported between Asian and Western countries. Of particular interest is the prevalence of BRAF mutations, with Korean patients exhibiting the highest rate of BRAF-associated thyroid cancers in the world. Here, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer in Asians.
